Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chan Chen has a total of 310 co-authors. Here are the top co-authors by number of shared publications:

  • Hai Chen

    Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan, China

    22 shared publications
  • Rui Gao

    Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China

    19 shared publications
  • Tao Zhu

    Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China

    17 shared publications
  • Jin Liu

    Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu, China

    15 shared publications
  • Bo Jiao

    Department of Anesthesiology West China Hospital Sichuan University Chengdu Sichuan China

    13 shared publications
  • Tao Zhu

    University of South China

    13 shared publications

Latest Publications

  • Open Access

    Comparative effectiveness of digital health interventions for low back pain: systematic review and network meta-analysis of randomised controlled trials

    by Runfu Chen, Zhuotao Wu, Xiaojin Wei, Wenjie Yang, Caiyi Yan, Hai Chen, Xinyi Zeng, Kewen Ding, Xiaolin Xu, Xiaoyu Zhu, et al.

    Summary: Background: Digital health interventions are increasingly used for low back pain, but their comparative effectiveness across different delivery modalities, clinical outcomes, and follow-up periods remains uncertain. We aimed to compare the effects of major digital health modalities for adults with low back pain. Methods: We conducted a systematic review and frequentist random-effects network meta-analysis of randomised controlled trials. PubMed, Embase, CENTRAL, CINAHL, APA PsycINFO, ClinicalTrials.gov, and WHO ICTRP were searched from inception to March 19, 2026, and updated to Aug 8, 2026. Eight treatment nodes were compared: telemedicine, web applications, mobile applications, virtual reality, exergaming, biofeedback devices, face-to-face care, and control. Primary outcomes were pain intensity and physical function; secondary outcomes were pain-related fear avoidance, health-related quality of life, self-efficacy, anxiety, and depression. The review was registered with PROSPERO (CRD420261339841). Findings: We included 92 reports from 84 randomised controlled trials involving 11 803 participants. At post-intervention, virtual reality had the most favourable point estimate for pain intensity (SMD −1.43, 95% CI −1.87 to −0.98; moderate confidence). The estimate for physical function also favoured virtual reality (−0.86, −1.45 to −0.26), although confidence was very low. Virtual reality also probably reduced pain-related fear avoidance (−1.14, −1.68 to −0.61) and improved health-related quality of life (0.97, 0.57 to 1.36), both with moderate confidence. Other digital modalities showed favourable effects for selected outcomes, but confidence was generally low or very low. Networks became progressively sparse at later follow-up, and sustained effects were inconsistent. Global inconsistency was detected in the post-intervention pain-intensity network, with local inconsistency for selected exergaming comparisons. Interpretation: Digital health interventions for low back pain showed different effects across outcomes and follow-up periods. Virtual reality had the most favourable post-intervention estimates for pain intensity, pain-related fear avoidance, and health-related quality of life compared with control, with moderate confidence in these estimates. Larger head-to-head trials with longer follow-up are needed to determine whether these effects are sustained and to clarify the comparative effectiveness of digital interventions. Funding: National Key Research and Development Programme of China (2025YFC3607901). Research in context: Evidence before this study: We searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, CINAHL, APA PsycINFO, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform from database inception to March 19, 2026, and updated the search on Aug 8, 2026. We used terms related to low back pain, digital health technologies, and randomised trials, and screened the reference lists of systematic reviews. Previous reviews examined individual modalities, such as mobile applications, telehealth, or virtual reality, and used pairwise meta-analysis. Existing network meta-analyses either included broader chronic pain populations or compared a narrower range of rehabilitation approaches for low back pain. Although these reviews suggested that some digital interventions might improve pain or physical function, their relative effects across clinical outcomes and follow-up periods remained uncertain. To our knowledge, no previous synthesis had compared digital delivery modalities for low back pain across pain, physical function, and psychosocial outcomes while assessing confidence in the network estimates. Added value of this study: This systematic review and network meta-analysis included 92 reports from 84 randomised controlled trials involving 11 803 participants. We compared six digital modalities—telemedicine, web applications, mobile applications, virtual reality, exergaming, and biofeedback devices—with face-to-face care and control across seven outcomes and follow-up periods extending from treatment completion to 12 months or longer. Virtual reality had the broadest favourable estimates at post-intervention, including reductions in pain intensity and pain-related fear avoidance and improvement in health-related quality of life, all supported by moderate-confidence evidence. Other modalities showed favourable effects for selected outcomes, but no stable hierarchy was observed across outcomes and follow-up periods. Confidence in many estimates was low or very low, the post-intervention pain-intensity network showed inconsistency, and longer-term networks were sparse. These findings distinguish favourable post-intervention estimates from evidence of sustained comparative superiority. Implications of all the available evidence: Digital health interventions might support the management of low back pain, but the available evidence does not establish that any single delivery modality should be preferred. Although virtual reality produced the broadest favourable post-intervention estimates, evidence of sustained superiority was not established, and the observed effects cannot be separated reliably from differences in therapeutic content, treatment intensity, and clinician support. Selection of a digital intervention should therefore consider the intended treatment outcome, therapeutic components, accessibility, digital literacy, costs, and patient preferences. Adequately powered head-to-head trials with longer follow-up are needed, together with component-based studies that distinguish the contribution of the technological platform from that of the treatment it delivers.

  • Improving basic life support performance through student-generated assessment criteria: a randomized controlled trial

    by Caiyi Yan, Duo Li, Hongxia Sun, Xi Yang, Xiaojin Wei, Xiaoyu Zhu, Chunling Jiang, Qi Li, Chan Chen

  • Open Access

    Microglial Activation Is Associated with Hippocampal Synaptic Degeneration and Cognitive Deficits Following Repeated Propofol Exposure

    by Liyun Deng, Mengchan Su, Ying Cui, Jiahui Wu, Guo Chen, Ruotian Jiang, Chan Chen

    Propofol is a widely used intravenous anesthetic with recognized abuse potential; however, the effects of repeated propofol exposure on hippocampal function and cognition remain poorly understood. In the present study, we established a rat model of repeated subanesthetic intraperitoneal propofol administration and demonstrated that propofol induced robust conditioned place preference, indicating rewarding properties. Propofol-exposed rats exhibited significant impairments in hippocampus-dependent cognitive tasks. Transcriptomic analysis revealed marked transcriptional alterations enriched in pathways related to synaptic organization and plasticity following repeated propofol exposure. Consistently, Western blotting, transmission electron microscopy, and Golgi staining demonstrated pronounced reductions in dendritic spine density and synaptic integrity within the hippocampus. Moreover, aberrant microglial activation was observed in the hippocampus and was closely associated with synaptic degeneration and cognitive deficits. Importantly, pharmacological inhibition of microglial activation with minocycline effectively ameliorated propofol-induced cognitive impairment and synaptic degeneration. Collectively, these findings suggest that microglial activation is associated with hippocampal synaptic degeneration and cognitive deficits following repeated propofol exposure and may contribute to these pathological changes.

  • Open Access

    Genetic contributors to postoperative delirium and their implications for dementia outcomes

    by Kewen Ding, Xiaojin Wei, Yifei Tao, Sihan Chen, Changteng Zhang, Runfu Chen, Hai Chen, Xikun Han, Jiangning Song, Jin Liu, et al.

    Background: Postoperative delirium (POD) is a perioperative neurocognitive disorder that substantially impairs patient recovery. Unfortunately, its genetic risk profile and relationship with subsequent dementia remain unclear. We aimed to elucidate genetic contributors to POD identified via Hospital Episode Statistics codes and to examine its association with subsequent dementia. Methods: We included 230,179 non-cardiac and 21,254 cardiac surgery subjects from the UK Biobank, defining POD using ICD-10 delirium codes recorded within the first 7 postoperative days. Genome-wide association studies (GWAS) were performed in the non-cardiac and cardiac cohorts and their prespecified subgroups, followed by functional annotation, gene prioritization and drug-target analyses. Associations between POD and subsequent dementia were estimated using Cox models. Results: In the non-cardiac cohort, we identified one genome-wide significant locus at the APOE region, with rs429358 as the lead variant ( P =5.00×10 -28 ). Integrative gene prioritization analyses highlighted multiple genes within this locus. Exploratory drug-target analyses suggested potential subgroup-specific drug-target enrichment. In the cardiac cohort, no genome-wide significant signals were detected. POD was associated with all-cause dementia after both non-cardiac (HR=6.45, 95% CI 5.45-7.63) and cardiac (HR=2.95, 95% CI 1.71-5.08) surgeries. Conclusions: This study demonstrates APOE as a genetic risk locus for ICD-coded POD in the non-cardiac surgery setting and confirms an association between POD and subsequent dementia.


  • Open Access

    Targeting cardiomyocyte-derived extracellular vesicle miR-574-5p protects against cognitive impairment induced by ischemia–reperfusion

    by Erya Chen, Xiaoyu Zhu, Haiqing Chang, Qi Li, Zhenkun Zhao, Changteng Zhang, Yu Cao, Yajing Wang, Xinliang Ma, Tao Zhu, et al.

    Acute myocardial ischemia/reperfusion (MI/R) increases risk for cognitive decline, yet the underlying mechanisms mediating heart-brain communication remain


  • Open Access

    Premixed Lidocaine With Fospropofol Disodium for Safety and Clinical Evaluation Regarding Paresthesia Upon Fospropofol Disodium Injection: A Preclinical Experimental Study and a Randomized Controlled Trial

    by Bo Jiao, Xiaolin Xu, Ying Cui, Caiyi Yan, Liyun Deng, Dequan Zhong, Qing Yang, Jiqian Xu, Yi Liu, Xiaohui Sun, et al.

    Fospropofol disodium (fospropofol), a water‐soluble prodrug of propofol, reduces injection pain and anesthetic requirements but frequently causes paresthesia. Intravenous lidocaine has been shown to alleviate dexamethasone‐induced paresthesia, yet its effect on fospropofol‐related symptoms remains uncertain. We combined preclinical and clinical studies, first evaluating the safety and pharmacological changes of fospropofol premixed with lidocaine through in vitro and in vivo experiments and then conducting a randomized controlled trial in adult surgical patients to evaluate whether the lidocaine premixing strategy affects the occurrence of fospropofol‐induced paresthesia. In the preclinical study, the findings indicated that mixture of fospropofol and lidocaine remained physicochemically stable, with faster onset and longer sedation duration compared with fospropofol alone, without additional adverse effects. In the clinical trial, 74 patients received fospropofol dissolved in either 20 mL of normal saline or 0.75% lidocaine and 72 were included in the primary outcome analysis of paresthesia. This adverse reaction occurred in 83.3% of patients in both groups, mainly within 40–60 s after administration. No group differences were observed in plasma inflammatory markers and phosphate; however, phosphate levels increased postadministration in both groups. This study provides important guidance for clinical practice, showing that premixing lidocaine does not effectively alleviate paresthesia induced by fospropofol.


  • The Role of Toll-like Receptor 3 Signaling in Cognitive Impairment Induced by Propofol Addiction

    by Jiahui Wu, Liyun Deng, Rui Gao, Ying Cui, Yidan Tang, Changliang Liu, Tao Zhu, Chan Chen

    Growing preclinical and clinical evidence suggests that propofol has the potential for abuse and addiction. Clinical studies have investigated the association of propofol exposure with health, behavioral, and cognitive problems. Toll-like receptor 3 (TLR3) is a group of pattern recognition receptors in the innate immune system involved in the pathogenesis of psychiatric and neurological disorders, including neurodegeneration and drug abuse. However, whether TLR3 can be activated under propofol abuse conditions and contribute to the development of cognitive dysfunction has not been determined. Here, we demonstrated that propofol-induced attenuation of cognitive function and increased TLR3 expression in the hippocampus significantly enhanced neuroinflammation and impaired synapse formation in the hippocampus, ultimately leading to cognitive dysfunction. Mechanistically, the regulatory effects of TLR3 in propofol addiction were mediated by TLR3-mediated TRIF signaling. We further developed a propofol addiction model in TLR3 knockout mice and found that cognitive dysfunction and neuroinflammation were significantly reduced in TLR3 knockout mice. Thus, our results indicated that TLR3 contributes to propofol-induced cognitive impairment by enhancing neuroinflammation and impairing neuronal morphology in the hippocampus and might serve as a promising therapeutic target for the treatment of cognitive dysfunction caused by propofol abuse.